20/20 Biolabs, Inc. (AIDX) Stock

NASDAQ: AIDXHealthcare company in the medical devices industry, based in Gaithersburg, MD.

20/20 Biolabs stock price chart

AIDX interactive chart →

AIDX stock quote & key statistics

20/20 Biolabs earnings per share

Income →
Earnings per share

20/20 Biolabs revenue & net income

Income →
RevenueNet income

20/20 Biolabs annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$2.0M-$3.7M-$0.13
FY2024$1.8M-$5.6M—
FY2023$1.4M-$6.4M—
FY2022$11.1M$2.2M—
FY2021$9.6M$2.1M—

Fiscal year ending December 31. Source: company filings via EODHD.

About 20/20 Biolabs, Inc.

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.

20/20 Biolabs stock FAQ

What is the 20/20 Biolabs stock ticker symbol?

20/20 Biolabs, Inc. trades on the NASDAQ under the ticker symbol AIDX.

What sector and industry is 20/20 Biolabs in?

20/20 Biolabs, Inc. is classified in the Healthcare sector, Medical Devices industry.

How many employees does 20/20 Biolabs have?

20/20 Biolabs, Inc. has about 4 full-time employees.

What were 20/20 Biolabs's revenue and earnings last fiscal year?

20/20 Biolabs reported revenue of $2.0M and net income of -$3.7M in fiscal 2025, with earnings per share of -$0.13. Revenue grew 16.7% from the prior year.

When did 20/20 Biolabs go public?

20/20 Biolabs stock began trading on February 19, 2026.

Medical Devices stocks

All Healthcare stocks →